BioNTech shelves oral mRNA vaccine plans with Matinas
Pharmaceutical Technology
MAY 12, 2023
BioNTech has ended its research collaboration with Matinas after its oral mRNA vaccine failed to demonstrate preclinical activity. Matinas said it developed this unique formulation to “handle the physical complexity and biological fragility of mRNA”. Matinas announced the news in a May 10 statement.
Let's personalize your content